Search form


Press Releases

Axcan Pharma to Present at JP Morgan Healthcare Conference in San Francisco

Jan 09, 2004 - 12:00 ET

Axcan Pharma to Present at JP Morgan Healthcare Conference in San Francisco

MONT SAINT-HILAIRE, Quebec--Axcan Pharma Inc. ("Axcan" or the "Company") today
announced that on January 14, 2004, Léon Gosselin, President and Chief
Executive Officer of the Company, will make a presentation at the JP Morgan
Healthcare Conference held in San Francisco, CA. This presentation will take
place at 10:30 a.m. EST.

Interested parties can access the audio webcast of the presentation on the
Company's website at

Axcan is a leading specialty pharmaceutical company involved in the field of
gastroenterology.  The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

To the extent any statements made in this release contain information that is
not historical, these statements are essentially forward looking and are subject
to risks and uncertainties, including the difficulty of predicting FDA approvals,
acceptance and demand for new pharmaceutical products, the impact of competitive
products and pricing, new product development and launch, reliance on key strategic
alliances, availability of raw materials, the regulatory environment, fluctuations
in operating results and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission.

		Executive Vice President and Chief Operating Officer
		Axcan Pharma Inc.
		Tel: (205) 991-8085 ext. 223

or		Isabelle Adjahi
		Director, Investor Relations					
		Axcan Pharma Inc.
		Tel: (450) 467-2600 ext. 2000